Back to Browse Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 5

Augmentation treatment in major depressive disorder: focus on aripiprazole

Authors J Craig Nelson, Andrei Pikalov, Robert M Berman

Published 10 October 2008 Volume 2008:4(5) Pages 937—948


Review by Single-blind

Peer reviewer comments 3

J Craig Nelson1, Andrei Pikalov2, Robert M Berman3

1University of California San Francisco, San Francisco, California, USA; 2Otsuka Pharmaceutical Inc., Rockville, MD, USA; 3Bristol-Myers Squibb, Wallingford, CT, USA

Abstract: Major depressive disorder (MDD) is a disabling psychiatric condition for which effective treatment remains an outstanding need. Antidepressants are currently the mainstay of treatment for depression; however, almost two-thirds of patients will fail to achieve remission with initial treatment. As a result, a range of augmentation and combination strategies have been used in order to improve outcomes for patients. Despite the popularity of these approaches, limited data from double-blind, randomized, placebo-controlled studies are available to allow clinicians to determine which are the most effective augmentation options or which patients are most likely to respond to which options. Recently, evidence has shown that adjunctive therapy with atypical antipsychotics has the potential for beneficial antidepressant effects in the absence of psychotic symptoms. In particular, aripiprazole has shown efficacy as an augmentation option with standard antidepressant therapy in two, large, randomized, double-blind studies. Based on these efficacy and safety data, aripiprazole was recently approved by the FDA as adjunctive therapy for MDD. The availability of this new treatment option should allow more patients with MDD to achieve remission and, ultimately, long-term, successful outcomes.

Keywords: major depression, antipsychotic, mood disorder, aripiprazole

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] 


Other article by this author:

Long-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder

Berman R, Thase M, Trivedi M, Hazel JA, Marler S, McQuade R, Carson W, Baker R, Marcus R

Neuropsychiatric Disease and Treatment 2011, 7:303-312

Published Date: 24 May 2011

Readers of this article also read:

Rapid green synthesis of silver nanoparticles from Chrysanthemum indicum L and its antibacterial and cytotoxic effects: an in vitro study

Arokiyaraj S, Arasu MV, Vincent S, Udaya Prakash NK, Choi SH, Oh YK, Choi KC, Kim KH

International Journal of Nanomedicine 2014, 9:379-388

Published Date: 7 January 2014

Size-dependent antimicrobial properties of CuO nanoparticles against Gram-positive and -negative bacterial strains

Azam A, Ahmed AS, Oves M, Khan MS, Memic A

International Journal of Nanomedicine 2012, 7:3527-3535

Published Date: 10 July 2012

Ultrasound sonication with microbubbles disrupts blood vessels and enhances tumor treatments of anticancer nanodrug

Lin CY, Tseng HC, Shiu HR, Wu MF, Chou CY, Lin WL

International Journal of Nanomedicine 2012, 7:2143-2152

Published Date: 24 April 2012

Visualization of gold and platinum nanoparticles interacting with Salmonella Enteritidis and Listeria monocytogenes

Ewa Sawosz, André Chwalibog, Jacek Szeliga, et al.

International Journal of Nanomedicine 2010, 5:631-637

Published Date: 30 August 2010

Tunable drug loading and release from polypeptide multilayer nanofilms

Bingbing Jiang, Bingyun Li

International Journal of Nanomedicine 2009, 4:37-53

Published Date: 11 March 2009

Once-daily treatment of ADHD with guanfacine: patient implications

Brandon C Strange

Neuropsychiatric Disease and Treatment 2008, 4:499-506

Published Date: 6 June 2008

Agomelatine and its therapeutic potential in the depressed patient

Sidney H Kennedy, Beata S Eisfeld

Neuropsychiatric Disease and Treatment 2007, 3:423-428

Published Date: 15 September 2007

Understanding reported cognitive dysfunction in older adults with cardiovascular disease

John Gunstad, Ronald A Cohen, Robert H Paul, David F Tate, Karin F Hoth, Athena Poppas

Neuropsychiatric Disease and Treatment 2006, 2:213-218

Published Date: 15 June 2006